SMCypI C31_product_DataBase

Bioactivity	SMCypI C31 is a non-peptidic cyclophilin inhibitor with potent peptidyl-prolyl cis/trans isomerases (PPIase) inhibitory activity (IC50 of 0.1 µM). SMCypI C31 shows pangenotype anti-HCV activity with EC50s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction[1][2].
Target	IC50: 0.1 µM (Peptidyl-prolyl cis/trans isomerases (PPIase))
Invitro	SMCypI C31 (C31) inhibited the replication of genotype 1a, 1b, 2a, 3a, and 5a HCV-SGRs and chimeric genotype 2a/4a HCV-SGRs, with EC50 values of 3.80 µM, 2.95 µM, 2.30 µM, 7.76 µM, 1.20 µM and 1.40 µM, respectively[1].SMCypI C31 also inhibits the replication of the infectious J6/JFH1 virus, with an EC50 of 2.80 μM. SMCypI C31 inhibits DBN-3acc RNA replication in a dose-dependent manner, with a maximal 244-fold HCV RNA reduction at 10 μM[1].SMCypI C31 (C31) inhibits the replication of other members of the Flaviviridae family. SMCypI C31 inhibits viral replication of DENV (EC50 of 7.3 μM), YFV (EC50 of 27.2 μM), and ZIKV (EC50 of 48.0 μM)[1].
Name	SMCypI C31
CAS	2649904-85-6
Formula	C27H30N4O2S
Molar Mass	474.62
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Quentin Nevers, et al. Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity. Antimicrob Agents Chemother. 2018 Jun 26;62(7):e00126-18. [2]. Abdelhakim Ahmed-Belkacem, et al. Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. Nat Commun. 2016 Sep 22;7:12777.

PeptideDB

SMCypI C31

CAS: 2649904-85-6 F: C27H30N4O2S W: 474.62